We’re excited to announce the close of our $35M Series A financing! Atomic AI is fusing artificial intelligence and structural biology to unlock RNA drug discovery, designing RNA-targeted and RNA-based medicines to treat undruggable diseases. We're extremely thankful to all of our investors, including those participating in our Series A - Playground Global, 8VC, Factory, Greylock, Not Boring, AME Cloud Ventures, and renowned angel investors including GitHub ex-CEO Nat Friedman, Doug Mohr, Curai CEO Neal Khosla, and UC Berkeley professor and Arc Institute Co-founder Patrick David Hsu. https://lnkd.in/ggR7KnNB #ai #drugdiscovery #ml #rna
Atomic AI
Biotechnology Research
South San Francisco, California 3,447 followers
Rational design of new molecules and medicines, enabled by the fusion of artificial intelligence and structural biology.
About us
Atomic AI is a well-funded, early-stage biotech company transforming the rational design of molecules and medicines through the cutting-edge fusion of artificial intelligence and structural biology. Atomic’s unique R&D platform, based on research featured on the cover of Science (doi.org/10.1126/science.abe5650), provides new strategies to treat or cure previously-undruggable diseases by targeting RNA structure. We are an interdisciplinary team working across computational and experimental biology and believe that our strongest asset is our people. We're hiring! https://boards.greenhouse.io/atomai
- Website
-
https://atomic.ai
External link for Atomic AI
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- South San Francisco, California
- Type
- Privately Held
Locations
-
Primary
329 Oyster Point Blvd
South San Francisco, California 94080, US
Employees at Atomic AI
Updates
-
AI may be a cool tool, but it's a tool nonetheless, and not a panacea that's going to solve every single problem under the sun. It works well in areas where there's a significant amount of data associated with it; not so much in areas where there is not. So, what does this mean in #pharma? Atomic AI founder and CEO Raphael Townshend recently spoke to PharmTech about how #AI and #machinelearning can be best leveraged in #drugdiscovery, and where there are still gaps. Additional datasets are needed to address these limitations and push progress forward into the #drugdevelopment stages as well. 📺 Watch the interview: https://lnkd.in/engBrRYf 🕵🏽♀️ Learn how Atomic AI is generating RNA structural datasets and integrating machine learning foundation models with large-scale, in-house experimental wet-lab biology: https://lnkd.in/eTrdsXrw
-
We had a great time yesterday at #BIO2024! Thanks to everyone who attended our discussion about #AI in #drugdiscovery, as well as moderator Ayman AlAbdallah and fellow panelists Lee Cronin and Thomas Miller.
-
A must-attend #BIO2024 panel for anyone interested in #AIDrugDiscovery: Atomic AI founder & CEO Raphael Townshend will join other leaders to discuss the use of intelligent data acquisition, analysis and application of machine learning and AI in chemistry and structural biology. 🧮 New Tools, New Times: Chemical and Structural AI for Drug Discovery 🗓️ Wednesday June 5 ⌚ 1:45 - 2:45 pm PT 📍 24BC 🔹Ayman AlAbdallah, MBA, Partner, Mubadala Capital 🔹Lee Cronin, PhD, Founder and Chief Executive Officer, Chemify Limited 🔹Raphael Townshend, PhD, Founder & CEO, Atomic AI 🔹Thomas Miller, CEO and co-founder, Iambic Therapeutics https://lnkd.in/eqaxWV-u #drugdiscovery #drugdelivery #innovation #drugdevelopment #machinelearning #AI #structuralbiology
-
We are thrilled to announce the addition of Amanda Garner to Atomic’s Scientific Advisory Board. With her extensive, well-recognized and respected background in #RNA research and medicinal chemistry, her insight will be an incredible asset as we continue to push the boundaries of #drugdiscovery, merging #AI with structural biology to develop novel, more effective RNA medicines. Please join us in welcoming Dr. Garner to the Atomic team! Read more here: rb.gy/tjjn86
-
Atomic AI founder and CEO Raphael Townshend participated in a discussion with Secretary of State Antony J. Blinken during a visit to the Bay Area earlier this week. During the visit, Secretary Blinken met with a panel of industry and policy experts to talk about the nation's biotech and biomanufacturing industries and how they could best contribute to a sustainable, safe and secure American bioeconomy. Raphael shared his insights into the potential of #AI and the need for "strategic data reserves" supported by sustained investment from both the public and private sectors. The Secretary also heard calls for more resilient, sustainable pharmaceutical supply chains, with minimal disruptions to critical drug supplies and equitable access to essential medicines for all. See more here: rb.gy/3utmii #biosecurity #bioeconomy #biomanufacturing #biotech #AI
-
We’re looking forward to participating in next week’s #AlignSummit24!
Our second Align Summit is April 25 at the Royal Sonesta Boston, sponsored by Eli Lilly and Company. This partnering event connects funders looking to invest in innovation with startups developing the most ambitious and promising science. With our partners McKinsey & Company and Locust Walk, we’ve assembled 50+ pureplay biotech and artificial intelligence companies focused on R&D to present: https://lnkd.in/eTVFud8w. Read more about how MassBio is nurturing the Massachusetts ecosystem and advancing therapies closer to patients at Align Summit in this post from Chief Operating & Innovation Officer Jason Cordeiro: https://lnkd.in/e24U6TFw. #AlignSummit #AlignSummit24 #AIDrugDiscovery
Align Summit: Pairing ambitious science with funding partners - MassBio
https://www.massbio.org
-
How can we use foundation models to accelerate RNA-targeted drug discovery? Those participating in the #DrugDiscoveryChemistry event in San Diego this week can hear more about the evolution of the Atomic’s platform and its growing applications from Atomic's Head of Machine Learning Stephan Eismann. Not attending? You can learn more here: https://lnkd.in/emwVPwab #AI #ML #machinelearning #RNA #structuralbiology #drugdiscovery #drugdevelopment
-
At Atomic AI, our mission isn't just a statement—it's a commitment. We're using AI to uncover molecular structures & leverage RNA biology for breakthrough medicines. Join us in rewriting the script of disease treatment! https://atomic.ai/careers #RNAtherapeutics #RNA #RNAbiology #structuralbiology #AI #machinelearning #hiring #sciencejobs
-
Atomic AI reposted this
This should be a great event! I'm looking forward to moderating this panel of industry experts to discuss turning a platform into an asset.
I look forward to an exciting #paneldiscussion March 11-12 at Fierce Life Sciences Events with Mark DePristo BigHat Biosciences, Nnamdi Ihuegbu, PhD Genentech, Maria Luisa Pineda, PhD. Envisagenics and Mark Stead, PhD Atomic AI #platforms #assets #ai #products Insilico Medicine Fierce Pharma #businessdevelopment #licensing #drugdiscovery #drugdevelopment Register here: https://lnkd.in/gcZNSDba